Skip to main content

Botox News

Dose Requirements for Glabellar Botulinum Toxin Higher in High-Sun Climate

FRIDAY, July 19, 2024 – To achieve maximal paralysis, patients injected with glabellar botulinum toxin may have significantly higher dose requirements in a high sun-exposure environment, according...

CDC Reports Seven Cases of Illness After Possible Counterfeit Botox Injections

FRIDAY, July 12, 2024 – Seven patients with illness identified after presumed cosmetic botulinum neurotoxin (BoNT) product injection are described in a case report published in the July 11 issue of...

Fake Botox Shots Land 13 Women in Hospital

FRIDAY, July 12, 2024 – Seventeen women in nine states have fallen ill after getting fake Botox shots, with 13 of them landing in the hospital and one requiring a ventilator, a new report warns. In...

Targeted Diagnostic Botox Injections Can Identify Trigger Sites for Migraine

THURSDAY, May 9, 2024 – Diagnostic targeted Botox injections have high positive predictive value for migraine trigger site localization, according to a study published in the May issue of Plastic...

FDA Medwatch Alert: Counterfeit Versions of Botox Found in Multiple States

April 16, 2024 -- FDA is alerting health care professionals and consumers that unsafe counterfeit versions of Botox (botulinum toxin) have been found in multiple states and administered to consumers ...

CDC Warns of 19 Cases of Botched Botox Shots in 9 States

TUESDAY, April 16, 2024 – Counterfeit or mishandled Botox shots have triggered harmful reactions in 19 people in nine states, U.S. health officials warned Monday. In its alert, the U.S. Centers for...

FDA Approves Expanded Botox (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity

NORTH CHICAGO, Ill., July 29, 2021 /PRNewswire/ – Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of Botox® ...

Botox (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition

NORTH CHICAGO, Ill., Feb. 10, 2021 /PRNewswire/ – Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved Botox® for the treatment of ...

FDA Approves Expanded Botox (onabotulinumtoxinA) Label for the Treatment of Pediatric Patients with Spasticity

NORTH CHICAGO, Ill., July 9, 2020 /PRNewswire/ – Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License...

FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy

DUBLIN, Oct. 24, 2019 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application...

FDA Approves Botox (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity

DUBLIN, June 21, 2019 /PRNewswire/ – Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental biologics application (sBLA) for...

FDA Approves Botox (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity

DUBLIN, Jan. 22, 2016 /PRNewswire/ – Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has approved Botox...

FDA Approves Botox Cosmetic to Improve the Appearance of Crow’s Feet Lines

WEDNESDAY, September 11, 2013 – The U.S. Food and Drug Administration today approved a new use for Botox Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to...

FDA Approves Botox to Treat Overactive Bladder

January 18, 2013 – The U.S. Food and Drug Administration today expanded the approved use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who cannot use or do not adequately...

FDA Approves Botox to Treat Specific Form of Urinary Incontinence

SILVER SPRING, Md., Aug. 24, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Botox (onabotulinumtoxinA) injection to treat urinary incontinence in people with...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Chronic Migraine, Facial Wrinkles, Hyperhidrosis, Migraine Prevention, Migraine Prophylaxis, Overactive Bladder, Urinary Incontinence

Botox patient information at Drugs.com